130 related articles for article (PubMed ID: 11035135)
1. Effect of SR 49059, a V1a vasopressin receptor antagonist, in Raynaud's phenomenon.
Hayoz D; Bizzini G; Noël B; Depairon M; Burnier M; Fauveau C; Rouillon A; Brouard R; Brunner HR
Rheumatology (Oxford); 2000 Oct; 39(10):1132-8. PubMed ID: 11035135
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study.
Wise RA; Wigley FM; White B; Leatherman G; Zhong J; Krasa H; Kambayashi J; Orlandi C; Czerwiec FS
Arthritis Rheum; 2004 Dec; 50(12):3994-4001. PubMed ID: 15593189
[TBL] [Abstract][Full Text] [Related]
3. Effects of SR 49059, an orally active V1a vasopressin receptor antagonist, on vasopressin-induced uterine contractions.
Bossmar T; Brouard R; Döberl A; Akerlund M
Br J Obstet Gynaecol; 1997 Apr; 104(4):471-7. PubMed ID: 9141585
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers.
Brouard R; Laporte V; Serradeil Le Gal C; Pignol R; Jang H; Donat F; Lockwood G; Fournie D; Dreux F
Adv Exp Med Biol; 1998; 449():455-65. PubMed ID: 10026839
[TBL] [Abstract][Full Text] [Related]
5. Reproducibility of cold provocation in patients with Raynaud's phenomenon.
Wigley FM; Malamet R; Wise RA
J Rheumatol; 1987 Aug; 14(4):751-5. PubMed ID: 3668980
[TBL] [Abstract][Full Text] [Related]
6. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
[TBL] [Abstract][Full Text] [Related]
7. Digital pressure and flow measurement upon local cooling in Raynaud's disease. Effect of naftidrofuryl.
Bounameaux HM; Hellemans H; Verhaege R
Int Angiol; 1986; 5(1):39-44. PubMed ID: 3734514
[TBL] [Abstract][Full Text] [Related]
8. Digital vascular responses to cooling in subjects with cold sensitivity, primary Raynaud's phenomenon, or scleroderma spectrum disorders.
Maricq HR; Weinrich MC; Valter I; Palesch YY; Maricq JG
J Rheumatol; 1996 Dec; 23(12):2068-78. PubMed ID: 8970043
[TBL] [Abstract][Full Text] [Related]
9. Acute effects of misoprostol on digital circulation in patients with Raynaud's phenomenon.
Wise RA; Wigley F
J Rheumatol; 1994 Jan; 21(1):80-3. PubMed ID: 8151594
[TBL] [Abstract][Full Text] [Related]
10. Intravenous nicardipine in Raynaud's phenomenon: a controlled trial.
van Heereveld H; Wollersheim H; Gough K; Thien T
J Cardiovasc Pharmacol; 1988 Jan; 11(1):68-74. PubMed ID: 2450259
[TBL] [Abstract][Full Text] [Related]
11. Role of digital artery adrenoceptors in Raynaud's disease.
Cooke JP; Creager SJ; Scales KM; Ren C; Tsapatsaris NP; Beetham WP; Creager MA
Vasc Med; 1997; 2(1):1-7. PubMed ID: 9546943
[TBL] [Abstract][Full Text] [Related]
12. Effects of the nonpeptide V(1) vasopressin receptor antagonist SR49059 in hypertensive patients.
Thibonnier M; Kilani A; Rahman M; DiBlasi TP; Warner K; Smith MC; Leenhardt AF; Brouard R
Hypertension; 1999 Dec; 34(6):1293-300. PubMed ID: 10601133
[TBL] [Abstract][Full Text] [Related]
13. The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud's phenomenon.
Friedman EA; Harris PA; Wood AJ; Stein CM; Kurnik D
Clin Pharmacol Ther; 2007 Apr; 81(4):503-9. PubMed ID: 17301734
[TBL] [Abstract][Full Text] [Related]
14. Prazosin treatment of primary Raynaud's phenomenon.
Nielsen SL; Vitting K; Rasmussen K
Eur J Clin Pharmacol; 1983; 24(3):421-3. PubMed ID: 6345178
[TBL] [Abstract][Full Text] [Related]
15. The effectiveness of ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled study.
van de Wal HJ; Wijn PF; van Lier HJ; Skotnicki SH
Int Angiol; 1987; 6(3):313-22. PubMed ID: 3329207
[TBL] [Abstract][Full Text] [Related]
16. Raynaud's phenomenon in vibration syndrome: the impact of cold feet on skin temperature and vasomotion of the hand after immersion in cold water.
Falkenbach A; Watanabe I; Hartmann B; Agishi Y
Angiology; 1997 Dec; 48(12):1037-44. PubMed ID: 9404829
[TBL] [Abstract][Full Text] [Related]
17. A double-blind, randomized, placebo-controlled crossover trial of the α2C-adrenoceptor antagonist ORM-12741 for prevention of cold-induced vasospasm in patients with systemic sclerosis.
Herrick AL; Murray AK; Ruck A; Rouru J; Moore TL; Whiteside J; Hakulinen P; Wigley F; Snapir A
Rheumatology (Oxford); 2014 May; 53(5):948-52. PubMed ID: 24489014
[TBL] [Abstract][Full Text] [Related]
18. Acute effect of topical minoxidil on digital blood flow in patients with Raynaud's phenomenon.
Whitmore SE; Wigley FM; Wise RA
J Rheumatol; 1995 Jan; 22(1):50-4. PubMed ID: 7699682
[TBL] [Abstract][Full Text] [Related]
19. A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's syndrome.
Mohrland JS; Porter JM; Smith EA; Belch J; Simms MH
Ann Rheum Dis; 1985 Nov; 44(11):754-60. PubMed ID: 3904643
[TBL] [Abstract][Full Text] [Related]
20. A standardized finger cooling test for Raynaud's phenomenon: diagnostic value and sex differences.
Bartelink ML; Wollersheim H; Leesmans E; de Boo T; Thien T
Eur Heart J; 1993 May; 14(5):614-22. PubMed ID: 8508855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
